Roche: new data for multiple sclerosis
(CercleFinance.com) - Roche today announced that new OCREVUS (ocrelizumab) and ENSPRYNG (satralizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) next week (13-15 October 2021).
"These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS," the group said.
"Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations could help ensure access to treatment," it added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
"These data include 38 abstracts highlighting new longer-term efficacy and safety for both OCREVUS and ENSPRYNG, as well as our ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS," the group said.
"Additional data will show how a deeper scientific understanding of MS and NMOSD in diverse patient populations could help ensure access to treatment," it added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.